Diranersen Alzheimer’s Results: Biogen Tau Drug Slows Decline 38% at Two Years
Biogen's tau-lowering antisense drug diranersen slowed CDR-SB decline 38% at two years in the Phase 2 CELIA extension, up from 26% at 18 months. Full data, caveats and Phase 3…
